Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tinzaparin sodium - LEO Pharma/Novo Nordisk

Drug Profile

Tinzaparin sodium - LEO Pharma/Novo Nordisk

Alternative Names: Innohep; Logiparin

Latest Information Update: 10 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LEO Pharma; Novo Nordisk
  • Developer LEO Pharma
  • Class Antithrombotics; Glycosaminoglycans; Low molecular weight heparins
  • Mechanism of Action Factor Xa inhibitors; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Thrombosis
  • Phase III Venous thromboembolism

Most Recent Events

  • 28 Mar 2019 Hellenic Genito-Urinary Cancer Group (HGUCG) and Leo Pharma suspend the phase III PRONIA-CAT trial in Venous thromboembolism (Prevention) in Greece (SC) (EudraCT2018-001230-18)
  • 21 Feb 2019 Chemical structure information added
  • 30 Jan 2019 Phase-III clinical trials in Venous thromboembolism (Prevention) in Greece (SC) (EudraCT2018-001230-18)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top